Skip to main content

Biohaven

Biohaven Ltd is a commercial-stage biopharmaceutical enterprise headquartered in New Haven, Connecticut. The company specializes in the discovery, development, and commercialization of innovative therapeutics targeting neurological, psychiatric, and rare diseases, utilizing proprietary drug discovery platforms including glutamate modulation and myostatin inhibition. Principal revenue is derived through commercial pharmaceutical product sales of approved specialty medications and strategic pharmaceutical research licensing agreements. Biohaven Ltd is publicly listed on the New York Stock Exchange.

2 of the funds FundTelligence covers report a position in Biohaven.

Legal name
Biohaven Ltd
Sector
Health Care
Country
United States
Funds holding it
2

Funds holding Biohaven

Loading...